Back to top

Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on MaxCyte yesterday. The company’s shares closed yesterday at $1.13. Hewitt covers the He...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

MaxCyte, Inc. (MXCT)